Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06444880
Title	Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	M.D. Anderson Cancer Center
Indications	SMARCB1-deficient renal medullary carcinoma collecting duct carcinoma epithelioid sarcoma
Therapies	Cemiplimab + REGN4018 REGN4018
Age Groups:	adult \| senior \| child
Covered Countries	USA